-Synageva BioPharma will emerge from transaction as new public company with additional cash reserves and access to Fuzeon® royalty stream- -Supports focus on rapid clinical development of SBC-102 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results